NEUROGESX
NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's lead product candidate NGX-4010 is a dermal patch containing capsaicin, a selective TRPV1 agonist designed to manage pain associated with peripheral neuropathic p... ain conditions. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in 2000. NeurogesX is headquartered in San Mateo, California.
NEUROGESX
Industry:
Biotechnology Medical Medical Device Neuroscience
Founded:
1998-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.neurogesx.com
Total Employee:
11+
Status:
Active
Contact:
16503198757
Email Addresses:
[email protected]
Total Funding:
135.44 M USD
Technology used in webpage:
Confluence Networks Data Foundry
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
SV Health Investors
SV Health Investors investment in Post-IPO Equity - NeurogesX
Alta Partners
Alta Partners investment in Series D - NeurogesX
ARCH Venture Partners
ARCH Venture Partners investment in Series D - NeurogesX
Mitsubishi International Corporation (MIC)
Mitsubishi International Corporation (MIC) investment in Series D - NeurogesX
Global Life Science Ventures
Global Life Science Ventures investment in Series D - NeurogesX
Walden International
Walden International investment in Series D - NeurogesX
Montreux Equity Partners
Montreux Equity Partners investment in Series D - NeurogesX
University of North Carolina at Chapel Hill
University of North Carolina at Chapel Hill investment in Series C - NeurogesX
Diamond Capital Management
Diamond Capital Management investment in Series C - NeurogesX
ARCH Venture Partners
ARCH Venture Partners investment in Series C - NeurogesX
Official Site Inspections
http://www.neurogesx.com Semrush global rank: 5.76 M Semrush visits lastest month: 536
- Host name: acf3b736b777428f5.awsglobalaccelerator.com
- IP address: 15.197.240.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago